Discover
MIRA
MIRA Pharmaceuticals, Inc.
0.95
2 x 0.67
2 x 1.22
bid
ask
+
0.00
0.08%
2 @ 04:51 AM
0.92 -0.03 (2.88%)
| Ytd | -37.26% | |
| 1y | -21.71% |
0.92
day range
0.96
0.90
52 week range
2.45
| Open | 0.96 | Prev Close | 0.95 | Low | 0.92 | High | 0.96 | Mkt Cap | 39.81M |
| Vol | 31.85K | Avg Vol | 123.62K | EPS | -1.27 | P/E | N/A | Forward P/E | -2.14 |
| Beta | N/A | Short Ratio | 0.47 | Inst. Own | 5.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 1.00 | 200-d Avg | 1.25 | 1yr Est | 12.08 |
MIRA News
benzinga.com
MIRA Pharmaceuticals Announces New Preclinical Data On Mira-55 Cannabinoid Analog In Development For
Study Overview and Key FindingsResearchers tested THC and Mira-55, along with rimonabant's abili
accessnewswire.com
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism o
Data show Mira-55 does not produce the central nervous system effects associated with THC and acts t
benzinga.com
MIRA Pharmaceuticals Files Phase 2a Clinical Study Protocol To FDA For Ketamir-2 Oral NMDA Receptor
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage
benzinga.com
Mira Pharmaceuticals Appoints Andriy Mushak As Fractional CFO Following Departure Of CFO Alan Weichs
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
benzinga.com
MIRA Pharma Executes Amended And Restated Exclusive License Agreement With MIRALOGX, Securing Worldw
Agreement Establishes Global Exclusivity Across MIRA's Core Therapeutic Pipeline and Enhances St